Neuronetics (STIM) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
31 May, 2026Opening remarks and agenda
Meeting conducted in a virtual-only format with rules of order available online.
Attendance included board members, executive officers, and external auditors.
Overview of voting outcomes
Quorum confirmed with proxies representing a majority of outstanding shares.
All seven director nominees re-elected to the board.
Appointment of KPMG as independent auditor for 2026 ratified.
Advisory approval of executive compensation and approval of the 2026 Equity Incentive Plan.
Final voting results to be filed with the SEC within four business days.
Q&A with stakeholders
No questions were submitted regarding voting matters or in the Q&A portal.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Neuronetics
- Q2 2026 revenue up 9.1% to $41.6M, gross margin 51.1%, net loss narrowed, liquidity risks persist.STIM
Q2 2026 - Q1 revenue up 8% to $34.5M, net loss narrows, but going concern risk remains.STIMQ1 2026
- Votes sought for director elections, auditor ratification, compensation, and equity plan.STIMProxy filing
- Annual meeting to vote on directors, auditor, executive pay, and new equity plan, with strong governance focus.STIMProxy filing
- Over 20 million shares registered for resale post-acquisition, with no proceeds to the company.STIMRegistration Filing
- Q4 revenue up 86% YoY, 23% pro forma, with positive cash flow and 2026 growth outlook.STIMQ4 2025
- Q3 revenue up 4% to $18.5M; Greenbrook deal approved, boosting growth and synergies.STIMQ3 2024
- Acquisition and integration of Greenbrook TMS set the stage for growth and operational synergies.STIMCanaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024
- Record growth in new patient starts and adolescent market expansion set stage for 2025 breakeven.STIMThe 44th Annual William Blair Growth Stock Conference